MSLN and triple-negative breast carcinoma: (2023) taking Mesothelin (MSLN) as their target in triple-negative breast cancer (TNBC), they developed MSLN CAR-NK cells from induced pluripotent stem cells (iPSCs) whose efficiency was tested in several preclinical models (49).